Heron Therapeutics Inc. (HRTX) had a rough trading day for Friday October 04 as shares tumbled 10.04%, or a loss of $-1.945 per share, to close at $17.42. After opening the day at $18.17, shares of Heron Therapeutics Inc. traded as high as $18.49 and as low as $17.25. Volume was 6.84 million shares over 40,087 trades, against an average daily volume of n/a shares and a total float of 79.82 million.
As a result of the decline, Heron Therapeutics Inc. now has a market cap of $1.39 billion. In the last year, shares of Heron Therapeutics Inc. have traded between a range of $32.45 and $15.68, and its 50-day SMA is currently $n/a and 200-day SMA is $n/a.
Heron Therapeutics Inc is a commercial-stage biotechnology company. It is focused on improving the lives of patients by developing treatments that address some of the unmet patient needs. The company’s product portfolio consists of SUSTOL and CINVANTI. Its pipeline product is HTX-011.
Heron Therapeutics Inc. is based out of San Diego, CA and has some 198 employees. Its CEO is Barry D. Quart.
Heron Therapeutics Inc. is a component of the Russell 2000. The Russell 2000 is one of the leading indices tracking small-cap companies in the United States. It’s maintained by Russell Investments, an industry leader in creating and maintaining indices, and consists of the smallest 2000 stocks from the broader Russell 3000 index.
Russell’s indices differ from traditional indices like the Dow Jones Industrial Average (DJIA) or S&P 500, whose members are selected by committee, because they base membership entirely on an objective, rules based methodology. The 3,000 largest companies by market cap make up the Russell 3000, with the 2,000 smaller companies making up the Russell 2000. It’s a simple approach that gives a broad, unbiased look at the small-cap market as a whole.